Vanguard Capital Management’s Aptevo Therapeutics APVO Stock Holding History
Bought
Maintained
Sold
Other funds holding APVO
SM
Vanguard Capital Management's APVO Position: Q3 2026 in Review
Vanguard Capital Management held its Aptevo Therapeutics (APVO) position steady in Q3 2026 at 12,713 shares worth $23.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3970.
Vanguard Capital Management first reported a position in APVO in Q1 2026 and has held it in 3 quarters since. The position peaked at $56.4K in Q2 2026. 11 funds tracked by Wall St. Rank hold APVO as of Q3 2026.
- Vanguard Capital Management held 12,713 shares of Aptevo Therapeutics worth $23.1K as of Q3 2026.
- Vanguard Capital Management left its Aptevo Therapeutics share count unchanged in Q3 2026.
- Aptevo Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3970 holding.
- Vanguard Capital Management first reported a position in Aptevo Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Aptevo Therapeutics position peaked at $56.4K in Q2 2026.
- 11 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.